OXFORD, Miss., Nov. 13, 2006 (PRIMEZONE) -- Modern Technology Corp (Pink Sheets:MODC), a diversified technology development and acquisition company, announced today the immediate appointment to the Scientific Advisory Board of its bioscience operating subsidiary, Insight Medical Group, Mr. James S. Hartinger, MBA, CT (ASCP).
Mr. Hartinger, an industry veteran in cytopathology for 22 years, brings 12 years experience managing a major cytology lab, plus his national reputation as an expert in the diagnosis of human cancers. He was involved in 3 clinical trials of automated cytology machines. He collaborated with the major cancer diagnostic companies Cytyc, Tripath, Digene, and Neopath. Mr. Hartinger played a central role developing the AnuCyte cancer diagnostics system.
Mr. Hartinger brings vast experience and knowledge in the field of cancer diagnostics emanating from clinical work, cancer research, and product development. Mr. Hartinger maintains close relationships with executive and technical arms of all the major clinical labs, diagnostics companies, and HMOs. He has his finger on the pulse of the cancer diagnostics field.
Mr. Hartinger's close association with Insight Medical Group will provide the players in the field with the confidence and integrity they look for in considering a new approach to cancer diagnosis.
Some of his many publications include the following:
1. Bishop JW, Hartinger JS, Pawlick GS. Time Interval effect on
repeat Pap Smears. Acta Cytol. 1997;41(2):269-276
2. Manos M, Kinney WD, Hurely LB, Sherman ME, Shieh-Ngai J, Kurman
RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick
GF, Hiatt RA. Identifying Women with Cervical Neoplasia Using
Human Papillomavirus DNA testing for equivocal Pap results. JAMA
1999; 281: 1605-1610
3. Determining the Utility and Effectiveness of the Neopath AutoPap
300 QC System Used Routinely. Barbara Fetterman, S.C.T. (ASCP),
Gene Pawlick, M.D., Howard Koo, M.S., M.T. (ASCP), James
Hartinger, CT(ASCP), Carol Gilbert, CT(ASCP), C.M.I.A.C., and
Sheryl Connell. ACTA 1999
Anthony Welch, Chairman, said: "Mr. Hartinger is a stunning addition to an already world-class team. We are honored to include such an eminent name to the company's growing team. Dr. David Rasnick and Dr. Peter Duesberg have worked closely with Mr. Hartinger on the development of the AnuCyte system and Mr. Hartinger is a strong supporter of their work. He is a powerful ally for the company and the introduction of the AnuCyte cancer detection services to the international community of clinical and pathology labs. We have a historic technology and a team second to none."
AnuCyte is the only system in the world that can detect all cancers by analyzing the single trait common to all forms of cancer. This trait is not found in any healthy cell. The system rapidly and accurately identifies cancer at any stage in its development and also identifies healthy cancer-free cells in the same test. The system is unique in the world and can be applied to any form of cell sample suspected of cancer and return a reliable test result within minutes. The system completely eliminates heretofore unreliable, subjective, and error-prone pathology diagnosis of cancer and delivers an automated and completely objective measurement of the presence or absence of cancer with the highest accuracy rate of any diagnostic technology in the world. The AnuCyte system is the first and only system in the world that can accurately detect and assess the chromosomal imbalance of cancer in any tissue sample. This ability allows the system to quickly and accurately identify both cancerous and non-cancerous cells.
Dr. Rasnick and Dr. Duesberg have been prominent names internationally for many years for their research and publications. Investors may wish to read a recent article in Newsweek concerning the cancer research of Dr. Duesberg:
http://www.msnbc.msn.com/id/14757547/site/newsweek/
About Insight Medical Group
Insight Medical Group is a specialized biosciences development company whose mission is to bring world-changing medical technology and research to market in the areas of cancer and AIDS. The AnuCyte Cancer Detection System was invented by Dr. David Rasnick, Ph.D. The technology behind AnuCyte and the chromosomal imbalance theory is the result of 45 years of combined cancer research by Dr. David Rasnick, PhD and Dr. Peter Duesberg, Ph.D, who continues his studies on cancer research at the University of California, Berkeley.
About Modern Technology Corp
Modern Technology Corp, a diversified technology development and acquisition company, builds revenues through continuous growth, strategic acquisitions, and commercialization of nascent technology. MODC improves operating efficiencies through the elimination of cost redundancies and realized synergy between subsidiaries. Web Address: http://www.moderntechnologycorp.com
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.